Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)

NCT05050006 is registered in ClinicalTrials.gov with Instil Bio as lead sponsor.

NCT NCT05050006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Lead sponsor
Instil Bio
Phase
Phase 2
Overall status
Terminated
Start date
October 7, 2021
Completion date
February 27, 2023
Enrollment
29 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cutaneous melanoma